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Key message 
Cancer mortality rates in major Latin American countries are relatively low, except in Cuba. Still, they are 
predicted to decline moderately until 2017. Stomach and cervix rates remain high, though declining in all 
countries except cervix in Cuba. Estimated avoided cancer deaths in 1990-2017 are over 420,000 in 5 of the 
countries, but not in Brazil and Cuba, despite high rates in the latter.  
© The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical 
Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 
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Abstract 
Background: From most recent available data, we predicted cancer mortality statistics in selected Latin 
American countries for the year 2017, with focus on lung cancer. 
Materials and Methods: We obtained death certification data from the World Health Organization and 
population data from the Pan American Health Organization database for all neoplasms and selected 
cancer sites. We derived figures for Argentina, Brazil, Chile, Colombia, Cuba, Mexico and Venezuela. Using a 
logarithmic Poisson count data joinpoint model, we estimated number of deaths and age-standardized 
(world population) mortality rates in 2017. 
Results: Total cancer mortality rates are predicted to decline in all countries. The highest mortality rates for 
2017 are in Cuba, i.e. 132.3/100,000 men, and 93.3/100,000 women. Mexico had the lowest predicted 
rates, 64.7/100,000 men and 60.6/100,000 women. In contrast, the total number of cancer deaths is 
expected to rise due to population ageing and growth. Men showed declines in lung cancer trends in all 
countries and age groups considered, while only Mexican and Venezuelan women had downward trends. 
Stomach and (cervix) uteri rates are predicted to continue their declines, though mortality from these 
neoplasms remains comparatively high. Colorectal, breast and prostate cancer rates were predicted to 
decline moderately, as well as leukaemia. There was no clear pattern for pancreatic cancer. Between 1990 
and 2017 about 420,000 cancer deaths were avoided in 5 of the 7 countries, but no progress was observed 
in Brazil and Cuba. 
Conclusion: Cancer mortality rates for 2017 in the seven selected Latin American countries are predicted to 
decline, though there was appreciable variability across countries. Mortality from major cancers – including 
lung and prostate – and all cancers remains comparatively high in Cuba, indicating the need for improved 
prevention and management. 
 
 
Keywords: cancer, Latin America, mortality, projections, lung cancer, tobacco.  
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Introduction 
National cancer mortality data have been available for a few Latin American countries since the 1970’s. 
These showed relatively low rates for common cancers, including lung, colorectum and breast, in most 
countries, and relatively high rates, but with downward trends, for stomach and (cervix) uterus [1, 2]. 
Since death certification figures are available with a few years lag, predictions of cancer mortality for the 
current year have been published over several years for the USA [3] and the European Union (EU) [4], and 
have proven reasonably valid [3, 5]. Thus, despite some inherent uncertainty in any prediction, these are 
useful for public health planning, and for understanding patterns and trends in cancer rates and hence their 
major risk factors. 
We therefore predicted the number of deaths and mortality rates for all cancers and selected major cancer 
sites for 2017 in seven Latin America countries providing death certification data of acceptable validity to 
the World Health Organization (WHO) database. 
 
Materials and Methods 
We retrieved official death certification data from the WHO database (WHOSIS) [6] for cancer of the 
stomach, colorectum, pancreas, lung, breast, uterus (cervix and corpus), prostate, leukaemia and total 
neoplasms (malignant and benign). We obtained data for the 7 Latin American countries with over 85% 
death certification coverage (over 90% for all countries except Brazil) and over 10 million inhabitants 
(Argentina, Brazil, Chile, Colombia, Cuba, Mexico, and Venezuela) [7], for the 1980-2014 calendar period 
(for Venezuela and Colombia up to 2013). We obtained resident population estimates, based on official 
censuses, from the Pan American Health Organization (PAHO) database [8]. 
Using certified deaths and resident population, we calculated age-specific death rates for each 5-year age 
group (from 0-4 to 80+ years), sex and calendar year. We computed age-standardized rates per 100,000 
person-years at all ages, using the direct method on the world standard population. 
To identify the most recent trend segment, we fit a logarithmic Poisson count data joinpoint regression 
model to the number of certified deaths in each 5-year age group [9] allowing for up to five joinpoints. We 
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then applied a linear regression to each age group’s mortality data over the most recent trend segment 
identified by the joinpoint model to compute the predicted age-specific certified numbers of deaths and 
the corresponding 95% prediction intervals (PIs). We calculated the 95% PIs using a standard error 
accounting for the variability of the new observation [5, 10]. Predicted age-standardized death rates with 
their corresponding 95% PIs were estimated using the predicted age-specific death counts and the 
predicted population data from the PAHO database. 
Numbers of avoided cancer deaths over the 1990-2017 period were estimated by comparing observed 
deaths and expected ones on the basis of 1990 age-specific rates. 
 
Results 
Table 1 (men) and 2 (women) include the number of predicted cancer deaths and rates for the year 2017 
with the corresponding 95% PIs along with the 2012 observed data, and the percent difference between 
2017 and 2012 for the 7 countries and the 9 cancer sites considered. 
Figure 1 shows bar plots of age-standardized death rates per 100,000 population for all cancers in the 
countries considered, in men and women, in 2012 (dark grey), and the predicted rates for 2017 (light grey), 
with corresponding 95% PIs. Total cancer mortality is predicted to decline in all countries. In men the 
highest predicted rate is 132.3/100,000 for Cuba. Mexican men have the lowest predicted total cancer rate, 
64.7/100,000, and the largest fall in rates. In women, Cuba has the highest predicted rate 93.3/100,000, 
compared to 96.3 in 2012; Mexico has the lowest one, 60.6/100,000, compared to 65.8 in 2012. The 
greatest falls are predicted for Chile and Colombia.  
Despite favourable trends in rates, the number of deaths is predicted to increase in all countries and both 
sexes (Tables 1 and 2). The largest increase is in Colombian men. 
Figure 2 shows trends in total cancer mortality rates, in men and women separately, from 1980-84 
quinquennium to 2010-14, and predicted rates for 2017 with the corresponding PIs. In men trends started 
to decline between 1990 and 2000, except for Cuba and Brazil. Female trends generally declined over the 
whole period considered, except for Cuba and Brazil. 
5 
 
Figure 3 gives mortality trends for each cancer site and country. In men, lung cancer trends were 
moderately downwards in recent calendar periods for most countries. Mexico and Argentina showed 
strong downward trends since 1990. In contrast, lung cancer trends in women have been rising, except in 
Mexico, with however some levelling only in recent years. Stomach cancer mortality has long been 
downwards. Colorectal cancer has been rising in most countries, with a tendency to level off during the 
most recent period. Breast cancer mortality was relatively low in most countries (except Argentina) and 
tended to decline over recent years. In contrast, despite long term falls, cancer of the uterus rates remain 
high in all Latin America, particularly in Cuba and Venezuela, whose predicted rates remain around 
10/100,000. Prostate cancer rates were particularly high in Cuba and Venezuela, but tended to moderately 
decline over the most recent years. While pancreatic cancer rates are inconsistent, leukaemia mortality 
shows some declines over recent years. 
Table 3 presents all ages-standardized mortality rates for the age groups 25-44, 45-64, 65-74 and 75+ years 
for lung cancer in 2005-2009 and 2010-2014, the predicted rates for 2017 and the percent difference 
between 2012 and 2017. Men showed favourable patterns at all age groups and in all countries, generally 
larger in the young. With a few exceptions, rates were predicted to decline also in women, though 
generally not as much as for men. 
Figure 4 shows the estimated number of avoided cancer deaths in men and women between 1990 and 
2017, assuming constant age-specific rates in 1990 (light grey area). Over the 27-year period considered, a 
substantial amount of cancer deaths was avoided in Argentina (132,000 deaths, 88,000 in men and 44,000 
in women), Chile (63,000 deaths, 16,000 in men and 47,000 in women), Colombia (83,000 deaths, 31,000 in 
men and 52,000 in women), Mexico (118,000 deaths, 39,000 in men and 79,000 in women) and Venezuela 
only for women (26,000 deaths). No appreciable reduction in cancer deaths was observed in Brazil, Cuba 
and Venezuelan men. 
 
Discussion 
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Despite substantial variability across the seven Latin America countries considered (i.e., for all cancers in 
2012 there was an about two fold difference between the lowest rate in Mexico and the highest one in 
Cuba for men, and an over 50% difference in women), rates for all cancers and for most major cancer sites 
are predicted to fall to 2017, confirming the global decrease in cancer mortality over recent decades [11]. 
However, as in most other areas of the world with the exception of the USA and a few western European 
countries [4, 12], the total number of cancer deaths is still rising, reflecting the lower rate of falls as 
compared to the USA [3] and the EU [4], as well the increasing size and ageing of the population. 
Total cancer mortality rates in Argentina, Cuba and Chile were similar to those registered in Europe, North 
America and (for men) in Japan [11], but they were appreciably lower for both sexes in other Latin 
American countries considered. This essentially reflects the historical low lung cancer (and most likely other 
tobacco related cancers) rates in these countries, due to less frequent cigarette use [13-16]. However, in 
Cuba female lung cancer rates are higher than the EU ones, and not appreciably different from the North 
American ones [11], and rates are predicted to fall only modestly, contrary to the US ones [3]. 
Despite predicted continuous falls, stomach cancer rates remain high in Latin America (particularly so in 
Chile) [11]. This likely reflects the high prevalence of Helicobacter Pylori (HP) infection [17, 18] as well as the 
interaction between HP, unfavourable dietary habits and poor food preservation [19]. A meta-analysis of 
Latin American case control studies [20] confirmed the role of local dietary factors, i.e. meat, preserved 
meat, salt and chilli pepper on gastric cancer. 
In most of Latin America, and particularly in Mexico, colorectal cancer rates are much lower than in other 
areas of the world [11], despite a high prevalence of overweight and obesity [21, 22]. This likely reflects 
favourable aspects of local diet and possibly physical activity [23]. 
Pancreatic cancer mortality has not been increasing in most Latin American countries. This is consistent 
with the favourable patterns and trends of other tobacco-related cancers, since tobacco is the strongest-
recognised risk factor for this neoplasia, too [24]. Pancreatic cancer remains particularly difficult to 
diagnose, and hence a proportion of under-certification in some of the countries considered remains 
possible. 
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Breast cancer mortality has substantially declined in Europe and North America [3, 5] over the last few 
decades, following improvements in diagnosis and treatment. Most Latin American rates are comparably 
low, and show favourable predictions [25-27]. The low rates in Mexico are probably real, since breast 
cancer is easy to diagnose, and low breast cancer rates in these ethnic groups are registered in the USA as 
well [28-30]. 
We were unable to distinguish cervical from endometrial cancer from death certification data. The high 
rates in Latin America, however, are attributable to high cervical cancer [31] in this area. The predicted 
rates remain high on a global scale, despite substantial declines in all countries except Cuba. This underlines 
the persisting importance of prevention for this neoplasms [2, 32], through screening and – for younger 
generations - HPV vaccination. 
For prostate cancer, the predicted rates are favourable, reflecting, as in other areas of the world with 
similar rates, improved management [33]. Likewise, the favourable predictions in leukaemia rates are 
attributable to improved treatment of the disease [5, 34-36]. 
Over the last three decades, there was no appreciable number of cancer deaths avoided in Brazil and Cuba 
- despite the high rates in Cuba – as well as in men from Venezuela. This points to the urgency of improving 
cancer prevention and management in these countries [37]. The total number of avoided deaths in the 
other four countries plus Venezuelan women was over 420,000. This may be an underestimate, assuming 
that cancer deaths certification accuracy has improved over the last three decades. In proportional terms, 
this was less than in the USA and in the EU, but is at least in part justified by the comparatively low rates of 
several cancers in Latin America. 
Data available in the WHO database allowed analysis of trends and predictions for major cancers only in a 
proportion of Latin American countries, though these cover the majority of Latin American population. In 
some of the countries considered, validity of death certification may be subject to criticism, though we 
included only countries with acceptable indicators of death certification validity in the WHO database, and 
a selected number of major neoplasms relatively easy to diagnose and hence certify. In addition, this 
cannot explain the favourable predicted trends. It is moreover reassuring that the presented cancer rates 
8 
 
and patterns are consistent with those of selected groups of Hispanic whites in Florida, i.e. Mexican, Cuban, 
Central America, South America [30]. Another inherent limitation of predictions is their inability to model 
sudden changes or fluctuation in slope. These limitations notwithstanding, the general pattern emerging 
from the present work is of continuing, though modest, declines in cancer mortality in Latin America, with 
the exception of Cuba [30]. 
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Figure legends 
Figure 1. Bar-plots of age-standardized (world population) death rates per 100,000 persons for the year 
2012 (dark grey) and predicted rates for 2017 (light grey) with 95% prediction intervals (PIs) for total cancer 
in the 7 selected Latin American countries, men and women.  
Figure 2. Age-standardized (world population) total cancer mortality rate trends in quinquennia from 1980 
to 2014 and predicted rates for 2017 with 95% prediction intervals (PIs), for Argentina (squares), Brazil 
(circles), Chile (triangles), Colombia (crosses), Cuba (xs), Mexico (diamonds), and Venezuela (inverted 
triangles), in men and women. 
Figure 3. Age-standardized (world population) cancer mortality rate trends in quinquennia from 1980 to 
2014 and predicted rates for 2017 with 95% prediction intervals (PIs) for the 7 selected Latin American 
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countries. Men: stomach (squares), colorectum (circles), pancreas (triangles), lung (crosses), prostate 
(inverted triangles) and leukaemias (ticked squares). Women: stomach (squares), colorectum (circles), 
pancreas (triangles), lung (crosses), breast (xs), uterus (diamonds) and leukaemias (ticked squares). 
Figure 4. Total avoided cancer deaths for 5 of the 7 Latin American countries considered, in both sexes 
between the top rate in 1990 and 2017 (light grey area); observed numbers of cancer deaths from 1990 to 
2013/2014 and predicted cancer deaths from 2014/2015 to 2017 (black line); estimated numbers of total 
cancer deaths by applying 1990 age-specific peak mortality rate (dark grey). During the 27 years period a 
total of over 420,000 cancer deaths have been avoided in 5 of the 7 countries considered (174,000 in men 
and 248,000 in women). No reduction in cancer deaths was registered in Brazil, Cuba and Venezuelan men. 
In 2017 alone about 30,000 deaths are predicted to be avoided in men, but none in Cuba, and about 26,000 
in women, but none in Brazil and Cuba. Abbreviation: ASR, age specific rate. 
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Table 1. Number of predicted deaths and mortality rates per 100,000 men for the year 2017 and 
comparison figures for the year 2012, from selected Latin America countries, with 95% prediction intervals. 
MEN 
Observed 
number 
of deaths 
2012 
Predicted 
number 
of deaths 
2017 
Lower 
prediction 
limit 
(95%) 
Upper 
prediction 
limit 
(95%) 
Observed 
ASR* 
2012 
Predicted 
ASR* 
2017 
Lower 
prediction 
limit 
(95%) 
Upper 
prediction 
limit 
(95%) 
% 
difference 
2017 
versus 
2012 
Argentina STOMACH 1856 1830 1730 1935 7.47 6.78 6.41 7.16 -9.2 
COLORECTUM 3953 4330 4160 4495 15.38 15.51 14.91 16.11 0.9 
PANCREAS 1829 2000 1898 2098 7.41 7.29 6.93 7.66 -1.5 
LUNG 6422 6090 5862 6316 26.73 22.73 21.86 23.59 -15.0 
PROSTATE 3746 3590 3388 3790 12.99 11.32 10.73 11.92 -12.8 
LEUKEMIAS 899 980 907 1044 3.74 3.75 3.46 4.03 0.2 
ALL CANCERS 32349 33000 32439 33559 129.47 119.84 117.78 121.89 -7.4 
Brazil STOMACH 8716 9310 9099 9520 9.20 8.17 7.99 8.36 -11.2 
COLORECTUM 9048 10950 10686 11205 9.50 9.56 9.33 9.79 0.6 
PANCREAS 4017 4810 4649 4974 4.26 4.24 4.10 4.39 -0.5 
LUNG 14268 15970 15692 16248 15.29 14.11 13.85 14.36 -7.7 
PROSTATE 13353 14980 14608 15357 14.04 12.64 12.31 12.97 -10.0 
LEUKEMIAS 3397 3420 3255 3583 3.53 3.14 2.99 3.28 -11.1 
ALL CANCERS 102153 115300 114197 116400 107.52 101.04 100.06 102.01 -6.0 
Chile STOMACH 2181 2190 2076 2311 19.91 16.68 15.78 17.58 -16.2 
COLORECTUM 1101 1230 1162 1305 9.85 9.32 8.78 9.87 -5.3 
PANCREAS 526 640 593 694 4.85 4.99 4.58 5.39 2.9 
LUNG 1680 1840 1715 1969 15.86 14.67 13.68 15.66 -7.5 
PROSTATE 2045 2180 2071 2296 16.26 14.35 13.62 15.08 -11.8 
LEUKEMIAS 380 370 333 411 3.76 3.28 2.89 3.66 -12.9 
ALL CANCERS 13148 14680 14312 15046 118.45 111.21 108.53 113.89 -6.1 
Colombia STOMACH 2811 2990 2862 3115 13.57 11.75 11.25 12.26 -13.3 
COLORECTUM 1528 1500 1369 1624 7.36 5.91 5.42 6.41 -19.7 
PANCREAS 649 750 692 800 3.18 2.96 2.74 3.18 -6.9 
LUNG 2332 2560 2404 2718 11.50 10.25 9.63 10.88 -10.8 
PROSTATE 2499 2730 2600 2862 12.07 10.61 10.10 11.12 -12.1 
LEUKEMIAS 858 960 896 1026 3.92 3.92 3.66 4.18 -0.1 
ALL CANCERS 18352 20940 20365 21524 88.28 82.99 80.70 85.28 -6.0 
Cuba STOMACH 514 550 507 595 5.41 5.16 4.70 5.62 -4.6 
COLORECTUM 1105 1160 1089 1231 10.97 10.33 9.64 11.01 -5.8 
PANCREAS 449 450 406 500 4.82 4.31 3.82 4.79 -10.6 
LUNG 3287 3400 3225 3584 35.17 31.89 30.19 33.58 -9.3 
PROSTATE 2711 2840 2584 3100 23.38 21.16 19.60 22.73 -9.5 
LEUKEMIAS 315 320 283 350 4.02 3.52 2.94 4.10 -12.6 
ALL CANCERS 13453 14500 14007 15000 139.93 132.31 128.37 136.26 -5.4 
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MEN 
Observed 
number 
of deaths 
2012 
Predicted 
number 
of deaths 
2017 
Lower 
prediction 
limit 
(95%) 
Upper 
prediction 
limit 
(95%) 
Observed 
ASR* 
2012 
Predicted 
ASR* 
2017 
Lower 
prediction 
limit 
(95%) 
Upper 
prediction 
limit 
(95%) 
% 
difference 
2017 
versus 
2012 
Mexico STOMACH 2910 2950 2836 3071 5.56 4.72 4.53 4.90 -15.1 
COLORECTUM 2741 2950 2789 3108 5.31 4.76 4.50 5.01 -10.4 
PANCREAS 1801 1880 1782 1976 3.58 3.07 2.90 3.24 -14.3 
LUNG 4067 3840 3666 4013 7.90 6.07 5.77 6.37 -23.2 
PROSTATE 5775 6400 6213 6588 10.35 9.41 9.14 9.68 -9.1 
LEUKEMIAS 2216 2300 2199 2401 3.83 3.56 3.41 3.72 -6.9 
ALL CANCERS 37946 41120 40511 41719 71.46 64.69 63.71 65.68 -9.5 
Venezuela STOMACH 1112 1230 1145 1314 9.20 8.41 7.83 9.00 -8.5 
COLORECTUM 827 940 883 1001 6.83 6.48 6.07 6.89 -5.2 
PANCREAS 451 440 399 478 3.78 3.02 2.74 3.29 -20.1 
LUNG 2038 2040 1919 2162 17.05 14.18 13.34 15.01 -16.8 
PROSTATE 2419 2690 2560 2823 20.70 18.80 17.89 19.70 -9.2 
LEUKEMIAS 495 510 465 550 3.67 3.34 3.06 3.61 -9.1 
ALL CANCERS 12781 13920 13393 14438 105.28 95.82 92.21 99.43 -9.0 
*ASR, age-standardized mortality rates using the World Standard Population. 
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Table 2. Number of predicted deaths and mortality rates per 100,000 women for the year 2017 and 
comparison figures for the year 2012, from selected Latin America countries, with 95% prediction intervals. 
WOMEN 
Observed 
number 
of deaths 
2012 
Predicted 
number 
of deaths 
2017 
Lower 
prediction 
limit 
(95%) 
Upper 
prediction 
limit 
(95%) 
Observed 
ASR* 
2012 
Predicted 
ASR* 
2017 
Lower 
prediction 
limit 
(95%) 
Upper 
prediction 
limit 
(95%) 
% 
difference 
2017 
versus 
2012 
Argentina STOMACH 1066 1040 962 1111 3.17 2.82 2.61 3.03 -10.9 
COLORECTUM 3419 3660 3526 3787 9.11 9.04 8.70 9.39 -0.7 
PANCREAS 2069 2220 2116 2326 5.67 5.50 5.21 5.78 -3.0 
LUNG 2735 3210 3072 3354 8.83 9.64 9.22 10.07 9.3 
BREAST 5491 5840 5586 6087 17.56 17.04 16.23 17.86 -2.9 
UTERUS (CERVIX AND CORPUS) 2583 2790 2667 2918 9.22 9.21 8.74 9.67 -0.2 
LEUKEMIAS 792 790 720 860 2.64 2.44 2.22 2.66 -7.7 
ALL CANCERS 29067 31560 30922 32205 88.73 88.88 87.15 90.62 0.2 
Brazil STOMACH 4990 5270 5093 5441 4.05 3.57 3.46 3.69 -11.7 
COLORECTUM 9717 11640 11320 11951 7.84 7.90 7.69 8.11 0.8 
PANCREAS 4206 4790 4634 4949 3.42 3.21 3.10 3.31 -6.2 
LUNG 9225 10450 9967 10935 7.80 7.43 7.10 7.76 -4.8 
BREAST 13590 15720 15426 16006 11.48 11.40 11.20 11.61 -0.7 
UTERUS (CERVIX AND CORPUS) 8683 9350 9086 9611 7.34 6.79 6.60 6.98 -7.4 
LEUKEMIAS 2954 3100 2985 3225 2.60 2.39 2.29 2.50 -8.1 
ALL CANCERS 89691 102410 101373 103439 74.74 71.96 71.21 72.71 -3.7 
Chile STOMACH 1173 1130 1044 1225 7.69 6.32 5.85 6.79 -17.9 
COLORECTUM 1199 1320 1234 1403 7.78 7.24 6.79 7.69 -7.0 
PANCREAS 610 730 652 799 4.06 4.11 3.63 4.60 1.4 
LUNG 1168 1090 996 1192 8.27 6.60 6.10 7.11 -20.2 
BREAST 1367 1390 1312 1471 10.16 9.13 8.64 9.61 -10.2 
UTERUS (CERVIX AND CORPUS) 849 860 790 920 6.47 5.56 5.08 6.03 -14.1 
LEUKEMIAS 315 330 298 368 2.65 2.42 2.10 2.73 -8.8 
ALL CANCERS 12284 13280 12988 13571 86.52 79.02 77.29 80.76 -8.7 
Colombia STOMACH 1839 1740 1618 1853 6.97 5.45 5.07 5.82 -21.9 
COLORECTUM 1610 1730 1609 1850 6.13 5.48 5.12 5.83 -10.6 
PANCREAS 779 920 868 965 3.04 2.93 2.77 3.09 -3.5 
LUNG 1725 1730 1621 1847 6.72 5.56 5.23 5.88 -17.4 
BREAST 2488 2630 2489 2773 9.69 8.71 8.25 9.18 -10.0 
UTERUS (CERVIX AND CORPUS) 1994 1930 1805 2054 7.82 6.36 5.95 6.77 -18.7 
LEUKEMIAS 808 810 745 871 3.23 2.91 2.68 3.15 -9.9 
ALL CANCERS 19184 20980 20558 21408 74.59 68.06 66.74 69.38 -8.7 
Cuba STOMACH 337 360 322 395 3.17 2.87 2.52 3.22 -9.6 
COLORECTUM 1376 1460 1409 1514 11.46 10.91 10.38 11.45 -4.7 
PANCREAS 382 470 424 508 3.50 3.76 3.39 4.12 7.3 
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WOMEN 
Observed 
number 
of deaths 
2012 
Predicted 
number 
of deaths 
2017 
Lower 
prediction 
limit 
(95%) 
Upper 
prediction 
limit 
(95%) 
Observed 
ASR* 
2012 
Predicted 
ASR* 
2017 
Lower 
prediction 
limit 
(95%) 
Upper 
prediction 
limit 
(95%) 
% 
difference 
2017 
versus 
2012 
LUNG 1831 2030 1929 2128 18.09 17.86 16.90 18.83 -1.3 
BREAST 1527 1550 1465 1636 14.86 13.71 12.94 14.48 -7.8 
UTERUS (CERVIX AND CORPUS) 1023 1170 1095 1244 10.75 10.83 9.97 11.69 0.8 
LEUKEMIAS 284 270 240 305 3.08 2.64 2.09 3.19 -14.2 
ALL CANCERS 9878 10810 10573 11054 96.32 93.25 90.72 95.78 -3.2 
Mexico STOMACH 2549 2700 2586 2813 4.21 3.72 3.55 3.89 -11.5 
COLORECTUM 2546 2780 2666 2890 4.23 3.87 3.71 4.03 -8.5 
PANCREAS 1959 2200 2111 2284 3.30 3.11 2.97 3.24 -5.9 
LUNG 2196 2400 2283 2525 3.67 3.33 3.16 3.51 -9.3 
BREAST 5525 5970 5793 6154 9.56 8.71 8.44 8.97 -9.0 
UTERUS (CERVIX AND CORPUS) 4559 4640 4460 4813 7.79 6.70 6.44 6.97 -14.0 
LEUKEMIAS 1874 1940 1853 2034 3.12 2.89 2.75 3.03 -7.3 
ALL CANCERS 38965 42590 42039 43138 65.84 60.59 59.76 61.41 -8.0 
Venezuela STOMACH 822 810 753 869 5.47 4.52 4.17 4.87 -17.3 
COLORECTUM 854 950 871 1031 5.82 5.38 4.92 5.84 -7.5 
PANCREAS 462 460 424 503 3.18 2.65 2.42 2.88 -16.8 
LUNG 1366 1410 1328 1492 9.60 8.08 7.59 8.58 -15.8 
BREAST 2067 2170 2037 2295 14.32 12.86 12.14 13.58 -10.2 
UTERUS (CERVIX AND CORPUS) 1853 1920 1830 2018 12.71 11.21 10.64 11.78 -11.8 
LEUKEMIAS 431 420 386 462 2.92 2.54 2.30 2.78 -13.1 
ALL CANCERS 12368 13710 13210 14206 84.74 80.08 77.33 82.83 -5.5 
*ASR, age-standardized mortality rates using the World Standard Population. 
5 
 
Table 3. Age-standardized lung cancer mortality rates for all ages, 25-44, 45-64, 65-74, 75+ years age groups in different selected Latin America countries, in 
men and women. 
 
Men  Women 
ASR* 
2005-2009 
ASR* 
2010-2014 
Predicted 
ASR 
2017* 
Lower 
prediction 
limit 
(95%) 
Upper 
prediction 
limit 
(95%) 
% difference 
(2017/2010-14) 
 
ASR* 
2005-2009 
ASR* 
2010-2014 
Predicted 
ASR 
2017* 
Lower 
prediction 
limit 
(95%) 
Upper 
prediction 
limit 
(95%) 
% difference 
(2017/2010-14) 
Argentina All ages 29.66 26.48 22.73 21.86 23.59 -14.2 8.06 8.96 9.64 9.22 10.07 7.60 
Truncated 25-44 years 2.60 2.01 1.06 0.56 1.56 -47.2 1.42 1.18 1.14 0.76 1.51 -3.80 
Truncated 45-64 years 68.89 57.71 47.64 44.81 50.47 -17.4 21.37 23.18 24.20 22.83 25.57 4.40 
Truncated 65-74 years 209.31 195.48 170.73 159.49 181.97 -12.7 45.74 56.12 67.55 61.56 73.55 20.40 
Truncated 75+ years 266.65 256.40 240.79 223.28 258.30 -6.1 65.01 69.89 67.17 61.31 73.02 -3.90 
Brazil All ages 16.47 15.33 14.11 13.85 14.36 -8.0 7.13 7.80 7.43 7.10 7.76 -4.70 
Truncated 25-44 years 1.34 1.13 0.93 0.79 1.06 -18.0 1.20 1.11 1.04 0.90 1.17 -6.50 
Truncated 45-64 years 30.80 27.76 25.74 24.98 26.49 -7.3 15.79 17.27 18.43 17.46 19.40 6.70 
Truncated 65-74 years 120.76 112.71 101.26 97.62 104.89 -10.2 45.77 51.22 43.14 38.57 47.72 -15.80 
Truncated 75+ years 209.11 203.58 193.19 187.93 198.46 -5.1 74.94 81.39 73.60 66.20 81.00 -9.60 
Chile All ages 16.89 16.36 14.67 13.68 15.66 -10.3 7.60 7.98 6.60 6.10 7.11 -17.30 
Truncated 25-44 years 1.08 0.93 0.88 0.46 1.30 -5.4 0.65 0.75 0.81 0.49 1.13 8.20 
Truncated 45-64 years 30.47 27.42 25.55 22.87 28.24 -6.8 14.56 15.00 12.67 11.15 14.19 -15.50 
Truncated 65-74 years 132.08 134.65 124.13 110.46 137.80 -7.8 56.01 58.71 48.21 41.89 54.52 -17.90 
Truncated 75+ years 207.15 207.03 167.78 143.51 192.06 -19.0 91.73 98.98 77.96 65.15 90.76 -21.20 
Colombia All ages 14.02 12.14 10.25 9.63 10.88 -15.5 7.22 6.62 5.56 5.23 5.88 -16.10 
Truncated 25-44 years 1.18 0.88 0.73 0.45 1.01 -16.9 0.87 0.76 0.79 0.56 1.02 3.90 
Truncated 45-64 years 20.92 17.58 14.94 13.76 16.11 -15.0 11.18 10.38 9.10 8.42 9.79 -12.30 
Truncated 65-74 years 107.80 93.32 75.61 68.32 82.89 -19.0 56.75 47.91 37.65 34.72 40.59 -21.40 
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Men  Women 
ASR* 
2005-2009 
ASR* 
2010-2014 
Predicted 
ASR 
2017* 
Lower 
prediction 
limit 
(95%) 
Upper 
prediction 
limit 
(95%) 
% difference 
(2017/2010-14) 
 
ASR* 
2005-2009 
ASR* 
2010-2014 
Predicted 
ASR 
2017* 
Lower 
prediction 
limit 
(95%) 
Upper 
prediction 
limit 
(95%) 
% difference 
(2017/2010-14) 
Truncated 75+ years 212.44 192.65 171.68 149.54 193.82 -10.9 97.83 100.80 86.30 74.08 98.53 -14.4 
Cuba All ages 38.47 35.35 31.89 30.19 33.58 -9.8 18.67 18.79 17.86 16.90 18.83 -4.9 
Truncated 25-44 years 2.53 1.96 0.96 0.00 2.07 -50.8 2.15 1.76 1.76 0.77 2.75 0.0 
Truncated 45-64 years 81.84 70.34 60.31 54.55 66.07 -14.3 47.12 43.34 37.55 33.76 41.34 -13.4 
Truncated 65-74 years 256.19 265.60 257.18 235.77 278.60 -3.2 113.07 131.97 138.70 128.03 149.38 5.1 
Truncated 75+ years 468.92 406.71 365.49 332.44 398.53 -10.1 172.73 173.16 165.79 153.14 178.43 -4.3 
Mexico All ages 10.59 8.07 6.07 5.77 6.37 -24.8 4.46 3.90 3.33 3.16 3.51 -14.5 
Truncated 25-44 years 1.02 0.85 0.74 0.56 0.92 -13.0 0.72 0.68 0.63 0.51 0.75 -7.2 
Truncated 45-64 years 16.05 12.07 9.19 8.33 10.04 -23.9 8.23 7.17 5.81 5.20 6.42 -19.0 
Truncated 65-74 years 83.98 60.86 41.04 36.71 45.38 -32.6 32.06 27.09 22.85 20.96 24.75 -15.6 
Truncated 75+ years 151.36 123.70 102.15 96.12 108.19 -17.4 53.88 49.23 45.19 41.20 49.18 -8.2 
Venezuela All ages 17.93 17.23 14.18 13.34 15.01 -17.7 9.54 9.43 8.08 7.59 8.58 -14.3 
Truncated 25-44 years 2.04 1.60 1.26 0.84 1.69 -21.1 1.56 1.22 0.90 0.39 1.42 -25.8 
Truncated 45-64 years 38.12 36.94 28.86 26.04 31.68 -21.9 21.29 21.59 18.14 16.38 19.90 -16.0 
Truncated 65-74 years 116.66 110.81 98.03 89.31 106.76 -11.5 59.56 58.30 49.67 44.00 55.33 -14.8 
Truncated 75+ years 211.60 209.29 170.43 147.77 193.09 -18.6 103.11 102.58 94.16 85.17 103.16 -8.2 
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Figure 1. Bar-plots of age-standardized (world population) death rates per 100,000 persons for the year 
2012 (dark grey) and predicted rates for 2017 (light grey) with 95% prediction intervals (PIs) for total 
cancer in the 7 selected Latin American countries, men and women.  
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Figure 2. Age-standardized (world population) total cancer mortality rate trends in quinquennia from 1980 to 
2014 and predicted rates for 2017 with 95% prediction intervals (PIs), for Argentina (squares), Brazil 
(circles), Chile (triangles), Colombia (crosses), Cuba (xs), Mexico (diamonds), and Venezuela (inverted 
triangles), in men and women.  
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Figure 3. Age-standardized (world population) cancer mortality rate trends in quinquennia from 1980 to 
2014 and predicted rates for 2017 with 95% prediction intervals (PIs) for the 7 selected Latin American 
countries. Men: stomach (squares), colorectum (circles), pancreas (triangles), lung (crosses), prostate 
(inverted triangles) and leukaemias (ticked squares). Women: stomach (squares), colorectum (circles), 
pancreas (triangles), lung (crosses), breast (xs), uterus (diamonds) and leukaemias (ticked squares).  
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Figure 4. Total avoided cancer deaths for 5 of the 7 Latin American countries considered, in both sexes 
between the top rate in 1990 and 2017 (light grey area); observed numbers of cancer deaths from 1990 to 
2013/2014 and predicted cancer deaths from 2014/2015 to 2017 (black line); estimated numbers of total 
cancer deaths by applying 1990 age-specific peak mortality rate (dark grey). During the 27 years period a 
total of over 420,000 cancer deaths have been avoided in 5 of the 7 countries considered (174,000 in men 
and 248,000 in women). No reduction in cancer deaths was registered in Brazil, Cuba and Venezuelan men. 
In 2017 alone about 30,000 deaths are predicted to be avoided in men, but none in Cuba, and about 26,000 
in women, but none in Brazil and Cuba. Abbreviation: ASR, age specific rate.  
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